VistaGen Therapeutics - VTGN Stock Forecast, Price & News

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

VistaGen Therapeutics Stock Performance

Shares of VistaGen Therapeutics stock opened at $0.18 on Friday. The business's 50 day simple moving average is $0.71 and its 200 day simple moving average is $1.10. VistaGen Therapeutics has a 52-week low of $0.14 and a 52-week high of $3.26. The firm has a market cap of $36.16 million, a PE ratio of -0.73 and a beta of 0.53.

VistaGen Therapeutics (NASDAQ:VTGN - Get Rating) last announced its earnings results on Thursday, June 23rd. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). VistaGen Therapeutics had a negative net margin of 4,306.76% and a negative return on equity of 61.44%. During the same period last year, the business posted ($0.20) earnings per share. As a group, equities research analysts predict that VistaGen Therapeutics will post -0.28 EPS for the current year.

Analyst Upgrades and Downgrades

VTGN has been the subject of several recent analyst reports. William Blair downgraded VistaGen Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday, July 22nd. Jefferies Financial Group downgraded VistaGen Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, July 22nd. Maxim Group downgraded VistaGen Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, July 26th. Finally, Robert W. Baird downgraded VistaGen Therapeutics from an "outperform" rating to a "neutral" rating in a report on Friday, July 22nd.

Insider Activity at VistaGen Therapeutics

In other VistaGen Therapeutics news, major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business's stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $0.89, for a total transaction of $53,400.00. Following the transaction, the insider now owns 20,637,286 shares of the company's stock, valued at approximately $18,367,184.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.67% of the stock is owned by insiders.